Skip to main content
Premium Trial:

Request an Annual Quote

ElevateBio, Affini-T Partner on KRAS-Targeted Cell Therapy Development

NEW YORK – ElevateBio and Affini-T Therapeutics on Tuesday announced a partnership to develop Affini-T's engineered TCR-T therapies designed to target KRAS mutations in solid cancers.

For its part in the collaboration, ElevateBio will bring its BaseCamp facility and LentiPeak technology to engineer autologous cells to target KRAS in solid cancers. The firm's Waltham, Massachusetts-based good manufacturing practices-capable cell therapy center is set up to manufacture viral vectors and autologous, allogeneic, and regenerative cell and gene therapy products, and scale this production for research, clinical, or commercial use.

Affini-T, meanwhile, will contribute its T-cell receptor engineering platform, with which it selects and engineers immune cells to generate anti-tumor responses in immunosuppressive tumor microenvironments. Watertown, Massachusetts-based Affini-T uses this platform to engineer T cells for increased durability, persistence, and tumor infiltration.

"Deep expertise in autologous cellular therapies manufacturing and analytics combined with its scalable platform for suspension-based lentiviral production make ElevateBio an ideal partner as we progress our oncogenic driver programs into the clinic and work to deliver transformative therapies to patients and their families," Kim Nguyen, chief technical officer at Affini-T, said in a statement.